Friday, January 17, 2020 10:09:39 AM
Sent: Thursday, January 16, 2020 4:49 PM
To: ceo@creativemedicalhealth.com <ceo@creativemedicalhealth.com>; coo@creativemedicalhealth.com <coo@creativemedicalhealth.com>; Thomas Ichim <thomas.ichim@gmail.com>
Subject: 100X Higher - Dilution & Incompetence
Another 20 Million diluted today. Just think if you were not so incompetent and the PPS was 100 TIMES HIGHER like it would be if anyone else was running the company, you would have only needed to dilute 200,000 shares for the same amount of $$$.
Can you say Bankruptcy???
Recent CELZ News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/03/2023 08:05:12 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
- Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain • PR Newswire (US) • 09/19/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:45:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/29/2023 09:37:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/28/2023 01:00:18 PM
- Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements • PR Newswire (US) • 06/28/2023 12:00:00 PM
- Creative Medical Technology Announces $2 Million Share Repurchase Program • PR Newswire (US) • 06/12/2023 12:01:00 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 06/12/2023 12:00:00 PM
- Creative Medical Technology Holdings Announces Reverse Stock Split • PR Newswire (US) • 06/09/2023 04:30:00 PM
- Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform • PR Newswire (US) • 05/31/2023 12:00:00 PM
- Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development • PR Newswire (US) • 05/22/2023 12:30:00 PM
- Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line • PR Newswire (US) • 05/18/2023 12:00:00 PM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM